FUNDAMENTALS |
MarketCap: |
2.11 mill
|
EPS: |
0
|
P/E: |
0
|
Earnings Date: |
Nov 19, 2015 |
SharesOutstanding: |
21 096 mill
|
Avg Daily Volume: |
11.63 mill
|
RATING
2024-05-03 |
C+
|
Sell
|
RATINGS |
Rating CashFlow: |
Sell
|
|
Return On Equity: |
Sell
|
|
Return On Asset: |
Neutral
|
|
DE: |
Sell
|
|
P/E: |
Sell
|
|
Price To Book: |
Strong Sell
|
|
QUARTER GROWTHS |
|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | n/a | | | | | |
Asset | n/a | n/a | n/a | n/a | n/a | n/a |
Debt | n/a | | | | | n/a |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE 0 | sector: PE 29.05
|
PE RATIO: COMPANY / INDUSTRY |
N/A
|
Company: PE 0 | industry: PE 136.10
|
DISCOUNTED CASH FLOW VALUE |
N/A
|
N/A
|
Expected Trading Range (DAY) |
$ 0.0001 - 0.0001
( +/- 0.00%)
|
ATR Model: 14 days
|
Forecast:
16:00 - $0.0001
Live Trading Signals (every 1 min)
Forecast
1: 14:54 - $0
Forecast 2: 15:44 - $0
Forecast 3: 16:00 - $0.0001
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
Volume Signals |
Price |
$0.0001 (0.00% )
|
Volume |
19.94 mill
|
Avg. Vol. |
11.63 mill
|
% of Avg. Vol |
171.46 %
|
Signal 1: |
|
Signal 2: |
|
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VGLS
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
VG Life Sciences Inc., a biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation. It offers VG1177, a solution that deploys a synthesized peptide, which uses its superior binding abilities to eliminate the unwanted Class II-associated invariant chain peptide (CLIP) that is displayed on specific B cells that leads to chronic inflammation. The company also provides metabolic disruption technology (MDT) compounds impede tumor cells that sensitize cancer cells to treatment by disrupting the metabolic strategies those cells use to survive; and Hydroxychloroquine, a MDT compound that can be used in combination with other cancer drugs for treating drug-resistant cancers. In addition, it offers targeted peptide technology (TPT), a technology that eliminates the subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. VG Life Sciences Inc. was formerly known as Viral Genetics Inc. and changed its name to VG Life Sciences Inc. in November 2012. The company was founded in 1995 and is based in Santa Barbara, California. VG Life Sciences Inc. operates as a subsidiary of Feelux Co., Ltd.